Articles On Opthea (ASX:OPT)

Botanix Pharmaceuticals’ (ASX:BOT) shares have halved after its anti-acne drug failed its clinical trial. If you read most of the company’s announcement and you’d would have thought the 368 patient trial was a success. Its drug, BTX 1303, w...

What are Small-Cap Stocks? Small-cap stocks are the stocks, which have smaller market capitalisation or otherwise said as a small-sized company. Although small-cap stocks may not be on the priority of an investor as the market’s large-cap s...

It looks set to be a disappointing end to the week for the S&P/ASX 200 index. In afternoon trade the benchmark index is trading 0.6% lower at 6,643.1 points. Four shares that have not let that hold them back are listed below. Here’s wh...

The market may have dropped lower today, but that hasn’t stopped the Opthea Ltd (ASX: OPT) share price from racing higher. In morning trade the shares of the developer of novel biologic therapies for the treatment of eye diseases are up ov...

It’s paramount to hold equities that can capture alpha. By making bets on growth companies, this gives you a higher chance of boosting portfolio returns to complement your blue-chips. Here are 3 ASX companies that have grown exponentially...

Strong gains among selected life science shares is fuelling optimism the sector may have further to run. Life sciences stocks are involved in things like biotech, genetics, pharmaceuticals and medical devices. In a low growth earnings envir...

With the prospect of a global recession heightening, it’s important to have stocks in your portfolio with a strong likelihood of outperforming. Here are three ASX companies with defensible positions that are my picks for the long-haul. Ari...

This year has been a positive one for ASX small caps. According to Bloomberg, the average small cap has gained just under 5 per cent and some of the major sectors have seen double digit percentage gains. One example is the health sector whi...

Australian biopharmaceutical company Opthea (ASX:OPT) has announced the presentation of additional data from the recently completed 366 patient Phase 2b randomised controlled wet AMD study of OPT-302 with Novartis' PBS-listed LUCENT...

One of the best performers on the All Ordinaries index this year has been the Opthea Ltd (ASX: OPT) share price. Since the start of the year the shares of the developer of novel biologic therapies for the treatment of eye diseases have ral...

While these last few weeks have been filled with investor uncertainty, there have been clear outperformers. Recently, these 3 ASX healthcare shares have been popping up on my radar after posting strong FY19 results. If you’re looking to su...

The FDA’s decision on Clinvel Pharmaceuticals’ (ASX: CUV) SCENESSE treatment for erythropoietic protoporphyria capped off a stellar ride that’s lasted several years. Erthropoietic protoporphyria (EPP) is a rare skin order causing severe rea...

The Polynovo Ltd (ASX: PNV) share price is up 7% to $2.43 this lunchtime despite the biotech not releasing any specific news to the market. On September 23 the little-known surgical material business joined the S&P/ ASX200 (ASX: XJO) in...

The Orthocell Ltd (ASX: OCC) share price is up 25% to 50 cents today after the regenerative medicine researcher announced trial results showed its medical device CelGro® had helped quadriplegics regain arm and hand functions.  CelGro® is r...

Health care, being the dynamic sector, keep investors on their toes before injecting their funds. Vigilance to information is an important criterion that allows investors and market enthusiasts to capitalise money in the stocks. Variables p...

Analysts and CEOs of  companies targeting vision loss say there’s market opportunities above US$10 billion ($14.89 billion) for the taking. We aren’t talking about the entire vision loss market here. That’s $US10 billion worth of treatments...

According to Opthea CEO and managing director, Dr Megan Baldwin, “This R&D tax incentive credit of A$14.6 million increases the company’s cash balances to over A$30 million and will contribute to the execution and delivery of ou...

Mesoblast limited (ASX: MSB) shares are locked in a trading halt today with the regenerative medicine business reportedly seeking to raise another $75 million according to news reports in the Australian Financial Review. Mesoblast has often...

Now that reporting season is over, with the deadline for audited accounts passing yesterday, Stockhead recaps the ASX small caps that have won the attention of the most brokers. The most analysed small cap is lithium explorer Galaxy Resourc...

There’s an old saying — ‘an apple a day keeps the doctor away’. But these days, its biotechs — not apples — that are working hard to keep patients out of a congested medical system. Rhythm Biosciences (ASX: RHY) main asset is Colostat – a b...

This week’s recap of substantial holder transactions among ASX small caps covers everything from fund managers investing client cash to shares being handed down from one generation to the next. Substantial shareholders are shareholders hold...

The AVITA Medical Ltd (ASX: AVH) share price has been on fire again on Wednesday and has carved out another sizeable gain. In afternoon trade the regenerative medicine company’s shares are up 12.5% to 58.5 cents. This latest gain means tha...

A lot of retail share market traders like to pile into whatever’s hot or going up fast in the small-cap sector as they’re more interested in price action than the merits of the underlying business. In turn the hot money can amplify the sha...

Amidst global trade concerns and lower interest rate environment, investors are turning their investments into equity market. With Australia’s equity market offering decent returns, one sector that has garnered significant investor traction...

The S&P/ASX 200 index is on course to end its positive run with a disappointing decline on Tuesday. In afternoon trade the benchmark index is down 0.6% to 6,609.6 points. Four shares that have fallen more than most today are listed bel...

The share price of the Australian company developing a new eye therapy has quadrupled in recent weeks with its market capitalisation topping $900 million.

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

It’s not every day that a former doctoral student takes their thesis and turns it into a $1 billion venture, but that is just what Megan Baldwin has done at biotech outfit Opthea. Biotechnology is a crowded corner of the ASX which is filled...

The Opthea Ltd (ASX: OPT) share price is up 2.4% to $3.83 today after the eye disease treatment biotech updated investors on progress over its Phase 2b clinical trial into its OPT-302 with ranibizumab (Lucentis®) treatment compared to rani...

In morning trade the Domino’s Pizza Enterprises Ltd (ASX: DMP) share price has defied the market decline and pushed higher. At the time of writing the pizza chain operator’s shares are up almost 3% to $43.88. Why is the Domino’s share pric...

The Ramsay Health Care Limited (ASX: RHC) share price has been a strong performer in 2019. Since the start of the year the private hospital operator’s shares have risen a sizeable 15%. Is it too late to buy Ramsay Health Care’s shares? One...

The S&P/ASX 200 index is on course to start the week on a very disappointing note. In afternoon trade the index is down 0.7% to 6,558.3 points. Four shares that have not let that hold them back are listed below. Here’s why they are cha...

Last month the All Ordinaries index recorded its first monthly decline of the year after trade war and recession fears weighed heavily on global share markets. Whilst that was disappointing, it certainly didn’t stop the Opthea Ltd (ASX: OP...

On Wednesday the S&P/ASX 200 index has been up and down but is pushing higher in afternoon trade. At the time of writing the benchmark index is up 0.25% to 6,476.9 points. Four shares that have climbed more than most today are listed b...

The Opthea Ltd (ASX: OPT) share price has been one of the biggest movers on the All Ordinaries index on Wednesday. The shares of the developer of novel biologic therapies for the treatment of eye diseases raced a massive 21% higher to an a...

The Starpharma Holdings Limited (ASX: SPL) share price has been amongst the best performers on the All Ordinaries index on Wednesday. In morning trade the dendrimer products developer’s shares raced as much as 6% higher to $1.21 following...

A new month is upon us, so what better time to take a look at your portfolio and see if you can improve it with a few new additions. If you have space for a few small cap shares then I would consider adding one of these potential stars of...

Here’s our fortnightly wrap of all the news driving ASX small cap health stocks. We last checked in with ASX small cap health stocks just hours after Opthea’s (ASX:OPT) anti macular degeneration drug passed a large clinical test with flying...

On Stockhead today, investors should fall back in love with junior explorers once tech and cannabis lose their appeal, Opthea may need a bit of cash but it’s recent success has put it in a strong position, and Antler has invested $1.2m in p...

Coming after trial flops from Factor Therapeutics (ASX:FTT), Innate Immunotherapeutics (now Amplia Therapeutics, ASX:ATX) and Bionomics (ASX:BNO), investors were awaiting the phase IIb results from the eye diseases house with more than a de...

The S&P/ASX 200 index is on course to record a decline on Tuesday. In afternoon trade the benchmark index is down 0.2% to 6,575.5 points. Four shares that have fallen more than most today are listed below. Here’s why they are down in t...

The All Ordinaries index may be up materially this year, but some members of the index have thoroughly outperformed it. The two best performers on the index this year are listed below. Here’s why they are both up over 400% since the turn o...

In afternoon trade the S&P/ASX 200 index is on course to finish a volatile week on a positive note. At the time of writing the benchmark index is up 0.2% to 6,582 points. Four shares that have failed to follow the market higher today a...

Opthea (ASX: OPT) doubled on Wednesday after announcing its anti-AMD treatment (OPT-302) worked; but as CEO Megan Baldwin said yesterday, this was just the start. The announcement was just initial results of the trial – more detailed result...

Opthea (ASX:OPT), an Australian clinical-stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has reported positive results from its Phase 2b trial of OPT-302 for wet age-related macular degener...

On Stockhead today – the final wrap from Diggers and Dealers, the feds are finally on board with legal pot, and investors want ASIC to find some backbone. But first here’s what you need to know.   The day ahead If there’s one thing we can b...

The Australian share market returned to form on Wednesday following two consecutive days of heavy declines. This led to a number of shares pushing higher with the market, but some more than most. The three high-flying shares listed below h...

A one-day gain of 148 per cent has Opthea as comfortably the best-performing small cap health or biotech stock on the ASX at a time when the majority are trending downwards. Stockhead reported today on Opthea’s (ASX:OPT) positive results fr...

The ASX staged a recovery rally today after a sharp fall yesterday. Here’s some of the top performing ASX shares today. And today’s best performer was…Opthea Limited [ASX:OPT] The Opthea share price had a field day, going up by 136.99% in t...

The Opthea Ltd (ASX: OPT) share price has rocketed 130% to $2.02 this morning after it reported its OPT-302 combination therapy met the primary endpoint in a Phase 2b clinical trial.  According to the announcement the: “OPT-302 + Lucentis...